Forecast

The analysts' average price target is €7.74 (+50.00%). The median is €7.74 (+50.00%).

Buy	1
Hold	0
Sell	0

News Go to news feed

CapsoVision: Q2 loss widens, stock falls sharply in after-hours trading

CapsoVision reported Q2 revenue of $3.6 million (+10%) and an adjusted EPS of -$0.15, missing the consensus of -$0.11. Gross margin fell to 51% and operating expenses rose 46% to $9.5 million, pressured by development costs, tariffs and price competition. Management expects a stronger second half, plans a US launch of "AI Highlights" after expected FDA approval and has an ATM program of up to $100 million available; the stock dropped sharply after hours. » More on de.investing.com
CapsoVision introduces AI feature AI Highlights for CapsoCam Plus internationally

CapsoVision has announced the international launch of AI Highlights for the CapsoCam Plus system. The AI analyzes capsule endoscopy recordings during video processing, flags images suspected of clinically relevant findings, and is integrated into the CapsoView software and the CapsoCloud platform. The feature is available in markets where CapsoView/CapsoCloud are regulatory approved, including the EU; in the US, AI Highlights is not FDA‑approved and is not commercially available. The application is intended for trained medical professionals and does not replace clinical judgment. » More on de.investing.com

Financials

In the last quarter, CAPSOVISION INC had revenue of €3.19M and net profit of -€6.55M

(EUR)	June 2026	YoY
Revenue	3.19M	13.49%
Gross profit	1.64M	6.70%
Net profit	-6.55M	67.05%
EBITDA	-6.55M	71.31%

Fundamentals

Metric	Value
Market capitalization	€257.45M
Number of shares	49.96M
52-week high/low	€13.22 - €2.95
Dividends	No
Beta	-2.49
P/E ratio	-9.51
PEG ratio	0.33
P/B ratio	22.72
P/S ratio	21.55

Company profile

Medizintechnikunternehmen, das fortschrittliche Kapselendoskopiesysteme (CapsoCam Plus, CapsoCam Colon) und KI-gestützte Bildgebungsplattformen für die gastrointestinale Diagnostik entwickelt